Abbott Laboratories (ABT)
(Real Time Quote from BATS)
$112.85 USD
-0.25 (-0.22%)
Updated Aug 28, 2024 01:24 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Income Statements
Fiscal Year end for Abbott Laboratories falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 40,109 | 43,653 | 43,075 | 34,608 | 31,904 |
Cost Of Goods | 17,975 | 19,142 | 18,537 | 15,003 | 13,231 |
Gross Profit | 22,134 | 24,511 | 24,538 | 19,605 | 18,673 |
Selling & Adminstrative & Depr. & Amort Expenses | 15,656 | 16,149 | 16,113 | 14,248 | 14,141 |
Income After Depreciation & Amortization | 6,478 | 8,362 | 8,425 | 5,357 | 4,532 |
Non-Operating Income | 823 | 502 | 319 | 157 | 215 |
Interest Expense | 637 | 558 | 533 | 546 | 670 |
Pretax Income | 6,664 | 8,306 | 8,211 | 4,968 | 4,077 |
Income Taxes | 941 | 1,373 | 1,140 | 497 | 390 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 5,723 | 6,933 | 7,071 | 4,471 | 3,687 |
Extras & Discontinued Operations | 0 | 0 | 0 | 24 | 0 |
Net Income (GAAP) | 5,723 | 6,933 | 7,071 | 4,495 | 3,687 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 9,721 | 11,629 | 11,963 | 8,684 | 7,546 |
Depreciation & Amortization (Cash Flow) | 3,243 | 3,267 | 3,538 | 3,327 | 3,014 |
Income After Depreciation & Amortization | 6,478 | 8,362 | 8,425 | 5,357 | 4,532 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 1,749.00 | 1,764.00 | 1,789.00 | 1,786.00 | 1,781.00 |
Diluted EPS Before Non-Recurring Items | 4.44 | 5.34 | 5.21 | 3.65 | 3.24 |
Diluted Net EPS (GAAP) | 3.26 | 3.91 | 3.94 | 2.50 | 2.06 |
Fiscal Year end for Abbott Laboratories falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 10,377.00 | 9,964.00 | 10,241.00 | 10,143.00 | 9,978.00 |
Cost Of Goods | 4,603.00 | 4,463.00 | 4,556.00 | 4,605.00 | 4,483.00 |
Gross Profit | 5,774.00 | 5,501.00 | 5,685.00 | 5,538.00 | 5,495.00 |
SG&A, R&D, and Dept/Amort Expenses | 4,105.00 | 4,115.00 | 3,905.00 | 3,891.00 | 3,953.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | 1,669.00 | 1,386.00 | 1,780.00 | 1,647.00 | 1,542.00 |
Non-Operating Income | 78.00 | 191.00 | 174.00 | 190.00 | 253.00 |
Interest Expense | 140.00 | 141.00 | 159.00 | 166.00 | 159.00 |
Pretax Income | 1,607.00 | 1,436.00 | 1,795.00 | 1,671.00 | 1,636.00 |
Income Taxes | 305.00 | 211.00 | 201.00 | 235.00 | 261.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 1,302.00 | 1,225.00 | 1,594.00 | 1,436.00 | 1,375.00 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 1,302.00 | 1,225.00 | 1,594.00 | 1,436.00 | 1,375.00 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 1,751.00 | 1,750.00 | 1,748.00 | 1,748.00 | 1,750.00 |
Diluted EPS Before Non-Recurring Items | 1.14 | 0.98 | 1.19 | 1.14 | 1.08 |
Diluted Net EPS (GAAP) | 0.74 | 0.70 | 0.91 | 0.82 | 0.78 |